Headache
-
Randomized Controlled Trial
Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
This study explored the dose-response relationship of carisbamate administered at doses of 100 mg per day, 300 mg per day, or 600 mg per day, in the prevention of migraine. ⋯ Carisbamate was not more efficacious in migraine prophylaxis than placebo in this well-controlled study that included a suitable population. However, carisbamate monotherapy was well tolerated at doses up to 600 mg per day.